CARLSBAD, Calif.–(BUSINESS WIRE)– ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today that the Company has received its European CE Mark certification for the ArtVentive EOS™ Peripheral Vascular Endoluminal Occlusion system.
“This is a very significant achievement in the Company’s history as it moves toward commercialization and its planned launch into the European markets,” stated Dr. Leon Rudakov, President and CTO. “The CE Mark also paves the way to facilitate approvals for the ArtVentive EOS™ device internationally in meeting with the Company’s global mandate,” stated Jim Graham, CEO and Chairman.
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with its corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device corporation committed to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).
The ArtVentive EOS™ system encompasses strategically innovative cutting edge devices that are unique, internationally patented and trademarked. The EOS device is catheter based and self-expandable serving for permanent or temporary (reversible) occlusion of body lumens (a cavity found within the vascular system and organ network within the body). The revolutionary device is based on a proprietary technology platform and will serve in many cases as a safe and reliable alternative to major surgery. This inventive breakthrough in technology is bringing the current interventional, image guided techniques to a new level of sophistication, resolving significant and unaddressed health issues.
The ArtVentive EOS device targets a substantive multi-billion dollar market demand in several major clinical areas including peripheral, neurovascular, women’s health (minimally invasive contraceptive device), interventional cardiology and pulmonary health issues.
More information about the Company can be found at www.artventivemedical.com.
This news release may include “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements are based on the beliefs by our management as well as assumptions made by and information currently available to the company. These statements reflect the company’s current views with respect to future events and are not guarantees of future performance. These statements may involve risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the said forward-looking statements. These factors include, among other things, the company’s periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. Except as required by law, the company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the company’s filings with the Securities and Exchange Commission which are available from the SEC’s EDGAR database at www.sec.gov, at various SEC reference facilities in the United States.
ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, CEO
Source: ArtVentive Medical Group, Inc.
View this news release online at: